PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibition and Stroke Prevention: Another Step Forward

Stroke. 2020 May;51(5):1361-1362. doi: 10.1161/STROKEAHA.120.028567. Epub 2020 Apr 21.
No abstract available

Keywords: Editorials; atrial fibrillation; cardiovascular disease; evolocumab; sample size; secondary prevention; stroke.

Publication types

  • Editorial
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized
  • Atherosclerosis*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors*
  • Proprotein Convertase 9
  • Stroke*
  • Subtilisins

Substances

  • Antibodies, Monoclonal, Humanized
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • PCSK9 protein, human
  • Proprotein Convertase 9
  • Subtilisins
  • evolocumab